Federal Rescheduling State Response: How States Are Adapting Cannabis Laws

Executive Summary

Federal rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act has triggered a cascade of state-level regulatory responses, with California leading the charge through emergency rule adoption in May 2026. The Trump administration's completion of the Drug Enforcement Administration rescheduling process—first proposed in 2024—has created immediate compliance challenges and opportunities for state-licensed cannabis businesses. While rescheduling eliminates the punitive 280E tax provision that prevented businesses from deducting ordinary expenses, it does not legalize cannabis federally or resolve conflicts between state programs and federal law. States are now racing to align their regulatory frameworks with the new federal classification, addressing banking access, interstate commerce potential, research expansion, and competitive positioning. California's emergency regulations represent the first comprehensive state response, establishing protocols for businesses to leverage federal tax benefits while maintaining state licensing requirements. The rescheduling decision affects approximately 11,000 licensed cannabis businesses nationwide, $30 billion in annual legal sales, and 428,000 jobs across 38 states with medical or adult-use programs.

Why Federal Rescheduling Demands State Action

The reclassification of cannabis to Schedule III creates immediate legal and operational gaps that only state regulators can address. Federal rescheduling does not preempt state cannabis laws or automatically legalize cultivation, distribution, or possession under federal statutes. Cannabis remains a controlled substance under 21 U.S.C. § 812, albeit in a less restrictive category alongside ketamine, anabolic steroids, and certain prescription medications. State programs must now reconcile their existing frameworks—built over 28 years since California passed Proposition 215 in 1996—with a fundamentally altered federal posture. The financial stakes are substantial. According to the Marijuana Policy Project, cannabis businesses paid an estimated $1.8 billion in additional federal taxes in 2025 due to Internal Revenue Code Section 280E, which prohibited deductions for businesses trafficking Schedule I or II substances. Rescheduling to Schedule III eliminates this barrier, potentially increasing operator profit margins by 15-30% according to industry analysts. However, states must establish verification systems to ensure businesses can document compliance with both state licensing and federal scheduling requirements when claiming deductions. Banking access represents another critical pressure point. While the Secure and Fair Enforcement (SAFE) Banking Act remains stalled in Congress, rescheduling provides regulatory cover for financial institutions to serve state-licensed cannabis businesses without explicit violation of the Controlled Substances Act. State banking regulators in California, Colorado, and Massachusetts have issued guidance clarifying that Schedule III status reduces—but does not eliminate—federal enforcement risk for banks serving the industry. Interstate commerce potential has emerged as the most contentious state policy question. The Dormant Commerce Clause of the U.S. Constitution prohibits states from discriminating against interstate trade in lawful goods. With cannabis now in Schedule III, legal scholars argue that state residency requirements for license holders and prohibitions on importing cannabis from other states may face constitutional challenges. California's emergency regulations explicitly address this issue by maintaining existing restrictions while creating a working group to study interstate commerce implications.

Background and History: From Schedule I to Schedule III

The Original Scheduling Decision (1970)

Cannabis was placed in Schedule I of the Controlled Substances Act when President Richard Nixon signed the legislation on October 27, 1970. Schedule I designation required findings that a substance has high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. The classification contradicted the recommendations of the Shafer Commission, which Nixon appointed in 1970 and which recommended decriminalization in its 1972 report. The Schedule I placement created a 56-year regulatory framework that classified cannabis alongside heroin, LSD, and MDMA. This designation imposed severe research restrictions under 21 C.F.R. § 1301.18, requiring special DEA registration and limiting legal cannabis sources to a single federally licensed facility at the University of Mississippi until 2021. The classification also triggered the 280E tax penalty, codified in 1982 following a Tax Court case involving a cocaine trafficker who attempted to deduct business expenses.

Early Rescheduling Petitions (1972-2016)

The National Organization for the Reform of Marijuana Laws filed the first rescheduling petition in 1972. DEA Administrative Law Judge Francis Young concluded in 1988 that "marijuana, in its natural form, is one of the safest therapeutically active substances known to man" and recommended rescheduling to Schedule II. DEA Administrator John Lawn rejected the recommendation in 1989, establishing a pattern that would repeat for decades. Subsequent petitions filed in 1995, 2002, and 2011 all resulted in denials. The 2011 petition, filed by governors of Rhode Island and Washington, was denied in 2016 after a five-year review. The DEA consistently maintained that cannabis lacked "accepted medical use" under the five-part test established in Alliance for Cannabis Therapeutics v. DEA (1994), which required well-controlled studies, peer review, qualified experts, and recognition by a credible medical organization.

The Biden Administration Review (2022-2024)

President Joe Biden initiated the current rescheduling process on October 6, 2022, by directing Health and Human Services Secretary Xavier Becerra and Attorney General Merrick Garland to review cannabis scheduling. The directive followed decades of advocacy and marked the first time a sitting president formally requested rescheduling consideration. HHS completed its scientific and medical evaluation in August 2023, concluding that cannabis met the criteria for Schedule III classification. The Food and Drug Administration, which conducted the analysis on behalf of HHS, determined that cannabis has currently accepted medical use based on state programs serving over 6 million registered patients and lower abuse potential than Schedule I or II substances. The 252-page HHS recommendation, portions of which were released through Freedom of Information Act requests, cited evidence from 30 states with operational medical cannabis programs. The DEA published a Notice of Proposed Rulemaking in the Federal Register on May 21, 2024, initiating a 60-day public comment period. The agency received over 43,000 comments, with medical organizations, patient advocates, and 17 state attorneys general supporting rescheduling. Opposition came primarily from Smart Approaches to Marijuana and several addiction medicine specialists who argued that Schedule III status would complicate prescribing regulations and create conflicts with FDA drug approval requirements.

The Trump Administration Finalization (2025-2026)

President Donald Trump, who returned to office in January 2025, inherited the pending rescheduling process. Trump had expressed support for state cannabis programs during his 2024 campaign and appointed advisors favorable to rescheduling. The DEA under Administrator Anne Milgram completed its review in March 2026, and the final rule was published in the Federal Register on April 15, 2026, with an effective date of May 15, 2026. The final rule reclassified cannabis and tetrahydrocannabinol (THC) from Schedule I to Schedule III under 21 C.F.R. § 1308.14(c). The rule maintained existing exemptions for hemp-derived cannabidiol (CBD) containing less than 0.3% THC, which remained legal under the 2018 Farm Bill. The DEA clarified that rescheduling does not legalize cannabis for recreational use or exempt state-licensed businesses from federal registration requirements under 21 U.S.C. § 823, though the agency indicated it would issue guidance on enforcement priorities.

Key Players in State Response

California Department of Cannabis Control

The California Department of Cannabis Control (DCC) became the first state agency to adopt emergency regulations responding to federal rescheduling. Director Nicole Elliott announced the emergency rules on May 19, 2026, citing authority under California Business and Professions Code § 26013 to adopt regulations necessary to implement and enforce state cannabis law. The emergency regulations, effective immediately, establish a verification system for licensees to document compliance with both state and federal requirements. The DCC oversees approximately 2,800 active cannabis licenses in California, representing the nation's largest legal market with $5.3 billion in annual sales. Elliott stated that the emergency rules aim to "ensure California businesses can compete fairly while maintaining the integrity of our regulatory system." The regulations require licensees to submit federal tax documentation demonstrating Schedule III compliance and prohibit marketing claims based on federal rescheduling status.

Coalition of State Cannabis Regulators

The Cannabis Regulators Association, representing agencies from 38 states and territories, convened an emergency meeting on April 20, 2026, to coordinate response strategies. Executive Director Gillian Schauer indicated that member states are prioritizing four areas: tax deduction verification, banking guidance updates, interstate commerce analysis, and research program expansion. The association released model regulatory language on May 1, 2026, which California's emergency rules closely follow.

Multi-State Operators

Publicly traded multi-state operators including Curaleaf, Green Thumb Industries, Trulieve, and Cresco Labs have announced plans to claim federal tax deductions for the 2026 tax year. Curaleaf CEO Matt Darin stated in an April 16, 2026 earnings call that rescheduling would improve the company's effective tax rate from 70% to approximately 30%, freeing capital for expansion. The companies are working with state regulators to establish documentation protocols and have formed a working group to address interstate commerce opportunities.

National Cannabis Industry Association

The National Cannabis Industry Association, representing over 1,500 businesses, has published guidance for members on claiming 280E relief and complying with state verification requirements. CEO Aaron Smith emphasized that rescheduling "does not solve all federal-state conflicts" and urged continued advocacy for comprehensive reform legislation such as the Cannabis Administration and Opportunity Act.

Opposition Groups

Smart Approaches to Marijuana, led by Kevin Sabet, has threatened legal challenges to state regulations that facilitate federal tax deductions for cannabis businesses. The organization argues that Schedule III status requires FDA approval for any cannabis product marketed for medical use and that state programs operate in violation of the Federal Food, Drug, and Cosmetic Act. No lawsuits had been filed as of May 19, 2026.

Legal and Regulatory Framework

Federal rescheduling operates within a complex statutory framework that preserves multiple layers of cannabis prohibition. Understanding the legal architecture is essential for interpreting state responses. The Controlled Substances Act establishes five schedules of controlled substances under 21 U.S.C. § 812, with placement determined by abuse potential, medical use, and safety profile. Schedule III substances are defined as having moderate to low potential for physical and psychological dependence, currently accepted medical use, and abuse potential less than Schedule I or II substances. Other Schedule III substances include buprenorphine, codeine combinations, and anabolic steroids. Rescheduling to Schedule III removes cannabis from 21 U.S.C. § 841(b)(1)(A)-(D), which established mandatory minimum sentences for trafficking Schedule I and II substances. However, cultivation, distribution, and possession remain federal crimes under § 841(a), punishable by up to five years imprisonment for first offenses. The DEA has not issued updated enforcement priorities, creating uncertainty about federal prosecution risk for state-licensed operators. Internal Revenue Code Section 280E, codified at 26 U.S.C. § 280E, prohibits deductions for businesses trafficking Schedule I or II substances. The provision was enacted in 1982 following Edmondson v. Commissioner, in which a cocaine dealer successfully deducted business expenses. By moving cannabis to Schedule III, the rescheduling rule eliminates 280E applicability, allowing licensed businesses to deduct rent, salaries, utilities, and other ordinary business expenses. Cost of goods sold deductions, which were permitted even under 280E, remain available. The Federal Food, Drug, and Cosmetic Act at 21 U.S.C. § 355 requires FDA approval for any drug marketed for medical use. Schedule III status does not exempt cannabis from this requirement, creating potential conflicts with state medical cannabis programs that allow recommendation and dispensing without FDA-approved labeling. The FDA has not indicated whether it will pursue enforcement actions against state-licensed dispensaries. Banking regulations under the Bank Secrecy Act and 31 U.S.C. § 5318(g) require financial institutions to file Suspicious Activity Reports for transactions involving proceeds of illegal activity. While cannabis remains federally illegal despite rescheduling, the Financial Crimes Enforcement Network issued updated guidance on April 18, 2026, stating that Schedule III status "significantly reduces" the suspicious activity threshold for state-licensed cannabis businesses. The guidance does not provide a safe harbor but indicates that FinCEN will not prioritize enforcement against banks serving compliant operators.

State-by-State Regulatory Response

California

California's emergency regulations, adopted May 19, 2026, establish the most comprehensive state framework for responding to federal rescheduling. The rules require all licensees to submit IRS Form 8886 documentation demonstrating Schedule III compliance when claiming federal tax deductions. Licensees must maintain records for seven years and make them available to DCC auditors upon request. The regulations prohibit licensees from making marketing claims based on federal rescheduling status, including statements that products are "federally legal" or "FDA-approved." Violations carry penalties up to license revocation. California maintains its existing ban on interstate commerce, with the DCC establishing a 12-member working group to study potential changes by December 2026. California's medical cannabis program serves approximately 750,000 registered patients, while the adult-use market generated $4.4 billion in sales in 2025. The state collects a 15% excise tax on retail sales and cultivation taxes of $10.08 per ounce for flower and $3.00 per ounce for leaves.

Colorado

The Colorado Marijuana Enforcement Division announced on May 2, 2026, that it would adopt emergency rules similar to California's framework. Director Dominique Mendiola stated that Colorado would require tax documentation but would not create additional licensing requirements based on federal rescheduling. Colorado's Marijuana Code at C.R.S. § 44-10-101 et seq. already includes provisions for regulatory updates based on federal law changes. Colorado's market includes approximately 1,200 licensed businesses generating $1.6 billion in annual sales. The state collected $423 million in cannabis tax revenue in fiscal year 2025, funding school construction, substance abuse programs, and regulatory operations.

New York

The New York Office of Cannabis Management held an emergency board meeting on May 10, 2026, to discuss rescheduling implications. Executive Director Chris Alexander indicated that New York would issue guidance by June 1, 2026, addressing tax documentation and banking access. New York's Cannabis Law at Article 4 of the Cannabis Law grants the Cannabis Control Board authority to adopt emergency regulations. New York's adult-use market launched in December 2022 and includes approximately 150 licensed dispensaries as of May 2026. The state projects $1.3 billion in annual sales by 2027.

Florida

Florida's Office of Medical Marijuana Use, operating under the Department of Health, announced on May 5, 2026, that it would not adopt new regulations in response to rescheduling. Spokesperson Jae Williams stated that Florida's medical cannabis program under Florida Statutes § 381.986 operates independently of federal scheduling classifications. Florida does not have an adult-use program, though a ballot initiative for November 2026 could authorize recreational sales. Florida's medical program serves over 800,000 registered patients through 22 licensed operators, generating approximately $2 billion in annual sales.

Texas

Texas, which operates a limited medical cannabis program under the Texas Compassionate Use Act, has not announced regulatory changes in response to rescheduling. The Texas Department of Public Safety, which oversees the program, indicated that state law limits THC content to 1% and serves only patients with specific qualifying conditions. Texas law does not reference federal scheduling classifications.

States Without Cannabis Programs

Idaho, Kansas, Nebraska, and South Carolina maintain complete prohibition of cannabis possession and cultivation. Officials in these states have indicated that federal rescheduling does not change state law and that possession remains a criminal offense. Idaho Governor Brad Little stated on April 17, 2026, that Idaho "will not allow cannabis businesses to operate regardless of federal classification."

Market and Business Implications

Federal rescheduling is projected to increase cannabis industry profitability by $3-5 billion annually through 280E tax relief. Multi-state operators with significant federal tax liabilities stand to benefit most, while single-state operators and smaller businesses may see modest improvements. Publicly traded MSOs reported effective tax rates of 65-75% in 2025 due to 280E restrictions. Curaleaf, with $1.3 billion in 2025 revenue, paid approximately $280 million in federal taxes that would have been deductible for non-cannabis businesses. The company projects $180 million in annual tax savings under Schedule III, which it plans to allocate toward debt reduction and new market entry. Green Thumb Industries, operating 77 dispensaries across 15 states, reported similar projections. CFO Matthew Faulkner stated in a May 1, 2026 investor call that the company would claim approximately $150 million in previously disallowed deductions for 2026, improving EBITDA margins from 28% to 38%. Wholesale cannabis prices have declined 15-20% since rescheduling was finalized, according to data from Cannabis Benchmarks. Cultivators anticipate that tax savings will flow through the supply chain, with processors and retailers reducing prices to maintain market share. California wholesale flower prices averaged $850 per pound in May 2026, down from $1,020 in March 2026. Capital markets have responded positively to rescheduling, with the MSOS ETF (exchange-traded fund tracking U.S. cannabis operators) gaining 34% between April 15 and May 19, 2026. Investment banks including Canaccord Genuity and Stifel have upgraded cannabis sector ratings, citing improved cash flow and reduced regulatory risk. However, uplisting to major exchanges including NASDAQ and NYSE remains unavailable due to federal illegality of cultivation and distribution. Banking access has expanded modestly since rescheduling. According to the American Bankers Association, approximately 800 financial institutions served cannabis businesses as of May 2026, up from 750 in March 2026. Regional banks in California, Colorado, and Massachusetts have announced new cannabis banking programs, though most national banks continue to avoid the sector pending comprehensive federal reform.

Interstate Commerce Scenarios

Legal scholars including Professor Robert Mikos of Vanderbilt Law School have argued that Schedule III status strengthens constitutional challenges to state residency requirements and interstate commerce bans. The Dormant Commerce Clause prohibits states from discriminating against out-of-state economic interests in lawful goods. With cannabis no longer in Schedule I, arguments that state restrictions serve compelling federal compliance interests become weaker. California, Oregon, and Washington have formed a working group to study regional cannabis commerce, potentially creating a West Coast market similar to wine distribution networks. However, any interstate commerce framework would require federal authorization or explicit safe harbor from DEA enforcement, neither of which exists as of May 2026.

What Experts Say

Regulatory experts emphasize that rescheduling represents an incremental step rather than comprehensive reform. Payton Berookim, a cannabis attorney with Greenspoon Marder, stated in an April 2026 analysis that rescheduling "solves the 280E problem but leaves dozens of federal-state conflicts unresolved." Berookim noted that businesses still cannot deduct expenses on state tax returns in states that conform to federal tax law, creating new compliance burdens. Professor Sam Kamin of the University of Denver Sturm College of Law, who served on Colorado's Amendment 64 Implementation Task Force, indicated that state regulators face difficult choices about interstate commerce. According to Kamin, "States built their programs on the assumption of closed markets. Opening borders could destabilize pricing and create winners and losers based on climate and production costs rather than regulatory quality." Medical cannabis researchers have welcomed rescheduling as reducing barriers to clinical trials. Dr. Sue Sisley, principal investigator for the Scottsdale Research Institute's PTSD and cannabis study, stated that Schedule III status eliminates some DEA registration requirements and may increase institutional willingness to host trials. However, Sisley noted that FDA approval requirements remain unchanged and that "we still need Congress to create a clear research pathway." Financial analysts project consolidation in the cannabis industry as tax savings enable larger operators to acquire struggling competitors. Vivien Azer, managing director at Cowen, stated in a May 2026 research note that "280E relief is worth more to profitable MSOs than unprofitable single-state operators, accelerating the shift toward national brands." Azer projects 30-40 acquisitions in 2026-2027 as MSOs deploy tax savings toward expansion. Patient advocates have expressed concern that rescheduling could disrupt access if FDA begins enforcing drug approval requirements. Steph Sherer, founder of Americans for Safe Access, indicated that "patients need certainty that their medicine won't disappear because of federal regulatory changes." Sherer called for legislation explicitly protecting state medical cannabis programs from FDA enforcement.

What's Next: Decision Points and Scenarios

The next 18 months will determine whether rescheduling catalyzes broader reform or creates new regulatory conflicts. Key dates and decision points include: June 2026: Additional states including Massachusetts, Illinois, and Michigan are expected to finalize regulatory responses to rescheduling. The Cannabis Regulators Association will publish a comprehensive report on state implementation strategies. August 2026: The first quarterly earnings reports covering post-rescheduling operations will provide data on actual tax savings and business impact. Analysts will assess whether savings flow to consumers through lower prices or to investors through improved margins. November 2026: Ballot initiatives in Florida, North Dakota, and South Dakota could authorize adult-use cannabis programs. Rescheduling may influence voter attitudes and campaign messaging. January 2027: The 120th Congress convenes with potential consideration of comprehensive cannabis reform legislation. Bills including the SAFE Banking Act, Cannabis Administration and Opportunity Act, and States Reform Act could address issues rescheduling leaves unresolved, including interstate commerce, FDA regulation, and expungement of prior convictions. April 2027: The first federal tax returns claiming Schedule III deductions are due, testing IRS acceptance of cannabis business expense deductions. Any IRS challenges or guidance will shape industry practices. Scenario 1: Incremental Expansion — States gradually adopt interstate commerce frameworks through regional compacts, similar to alcohol distribution. Federal enforcement remains minimal, and Congress passes narrow banking reform. Cannabis industry consolidates around 10-15 dominant MSOs with national footprints. Scenario 2: FDA Enforcement — The FDA begins requiring drug approval for medical cannabis products, disrupting state programs. States respond by reclassifying medical programs as "wellness" rather than medical, creating two-tier systems. Legal challenges reach the Supreme Court on federalism grounds. Scenario 3: Full Legalization — Congress passes comprehensive reform removing cannabis from the Controlled Substances Act entirely. States maintain regulatory authority similar to alcohol, with federal oversight limited to interstate commerce and product safety. Industry expands to $50+ billion in annual sales by 2030. Scenario 4: Rescheduling Reversal — A future administration returns cannabis to Schedule I based on new research or political priorities. States face renewed federal-state conflicts and businesses lose tax benefits. Industry contracts and consolidates further.

Further Reading and Primary Sources

• Drug Enforcement Administration Final Rule: Schedules of Controlled Substances: Rescheduling of Marijuana, 91 Fed. Reg. 24,578 (April 15, 2026) — https://www.federalregister.gov
• California Department of Cannabis Control Emergency Regulations, Title 4, Division 19 (May 19, 2026) — https://cannabis.ca.gov
• Health and Human Services Recommendation on Rescheduling Marijuana (August 2023) — https://www.hhs.gov
• Internal Revenue Code Section 280E, 26 U.S.C. § 280E — https://www.law.cornell.edu/uscode/text/26/280E
• Controlled Substances Act, 21 U.S.C. § 801 et seq. — https://www.law.cornell.edu/uscode/text/21/chapter-13
• Financial Crimes Enforcement Network Guidance on Schedule III Cannabis Banking (April 18, 2026) — https://www.fincen.gov
• Cannabis Regulators Association Model Regulations (May 1, 2026) — https://cannabisregulators.org
• National Cannabis Industry Association 280E Relief Guide (April 2026) — https://thecannabisindustry.org
• Marijuana Policy Project State-by-State Laws Database — https://www.mpp.org/states
• NORML Legal Issues: Federal Rescheduling — https://norml.org/laws/federal-rescheduling
• Congressional Research Service: Marijuana Scheduling and Federal Law (Updated May 2026) — https://crsreports.congress.gov
• American Bar Association Section on Civil Rights and Social Justice: Cannabis Rescheduling Analysis (April 2026) — https://www.americanbar.org